CTRI/2012/08/002846已完成3 期
A multinational, open label, randomized, active-controlled, 3-arm parallel group, 24-week study comparing the combination of glimepiride and metformin versus glimepiride and metformin alone in patients with type 2 diabetes - RECOMMEND
Sanofi Synthelabo I Ltd0 个研究点目标入组 1,116 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,116
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with type 2 diabetes mellitus, as defined by the World Health Organization diagnosed within one year prior to the screening visit, and not on antidiabetic agents for at least 3 months.
- •2. Signed informed consent, obtained prior to any study procedure.
排除标准
- •E 01. Diabetes other than type 2 diabetes (e.g. type 1 diabetes, diabetes secondary to pancreatic
- •disorders, drug or chemical agent intakeâ?¦).
- •E 02. HbA1c < 7.6% or > 9%.
- •E 03. Age < 18 or > 78 years old years.
- •E 04. Body mass index (BMI) > 35 kg/m².
- •E 05. Patients currently receiving or who have received any hypoglycemic agent within 3
- •months before screening visit.
- •Further details of exclusion criteria can be made available on request.
研究者
相似试验
进行中（未招募）
不适用
A randomised, open-label, multi-national, multi-center study to investigate the impact of bone-marker feedback (at 3 months) on adherence to once monthly ibandronate treatment of patients with post-menopausal osteoporosis (PMO) supported by PRP (patient relationship program). - BOUNCEMedDRA version: 8.1Level: PTClassification code 10031282osteoporosisEUCTR2005-005529-74-SIRoche (Hungary) Ltd.626
进行中（未招募）
1 期
A randomised, open-label, multi-national, multi-center study to investigate the impact of bone-marker feedback (at 3 months) on adherence to once monthly ibandronate treatment of patients with post-menopausal osteoporosis (PMO) supported by PRP (patient relationship program). - BOUNCEosteoporosisEUCTR2005-005529-74-SKRoche (Hungary) Ltd.626
进行中（未招募）
不适用
A randomised, open-label, multi-national, multi-center study to investigate the impact of bone-marker feedback (at 3 months) on adherence to once monthly ibandronate treatment of patients with post-menopausal osteoporosis (PMO) supported by PRP (patient relationship program). - BOUNCEMedDRA version: 8.1Level: PTClassification code 10031282osteoporosisEUCTR2005-005529-74-LVRoche (Hungary) Ltd.626
进行中（未招募）
不适用
A multi-national, open labelled, randomised, stratified, parallel group 36 week comparison of twice daily Biphasic Insulin Aspart 30 versus thrice daily Biphasic Insulin Aspart 50 and 70 all in combination with metformin in subjects with type 2 diabetes. (INTENSIMIX-trial)EUCTR2004-002778-50-BEovo Nordisk A/S750
进行中（未招募）
1 期
A multi-national, open labelled, randomised, stratified, parallel group 36 week comparison of twice daily Biphasic Insulin Aspart 30 versus thrice daily Biphasic Insulin Aspart 50 and 70 all in combination with metformin in subjects with type 2 diabetes. (INTENSIMIX-trial) - INTENSIMIX-trialEUCTR2004-002778-50-ESovo Nordisk A/S